Results 61 to 70 of about 3,160 (160)
In vivo models in breast cancer research: progress, challenges and future directions [PDF]
, 2017 Research using animal model systems has been instrumental in delivering improved therapies for breast cancer, as well as in generating new insights into the mechanisms that underpin development of the disease.
Baselga +8 more
core +5 more sources
The discovery of small-molecule modulators for the ACKR3 receptor [PDF]
, 2023 The atypical chemokine receptor 3 (ACKR3) is an attractive drug target for a new generation of chemotherapies. The inhibition of chemokine binding to ACKR3 by small-molecule agonists has shown reduced cancer activity in vivo and in vitro.
Riemens, Rick
core +1 more source
The role of ACKR3 in breast, lung, and brain cancer [PDF]
, 2020 Recent reports regarding the significance of chemokine receptors in disease have put a spotlight on atypical chemokine receptor 3 (ACKR3). This atypical chemokine receptor is overexpressed in numerous cancer types and has been involved in the modulation ...
Fumagalli, Amos +5 more
core +1 more source
Crosstalk between CXCR4/ACKR3 and EGFR signaling in breast cancer cells [PDF]
, 2022 A better understanding of the complex crosstalk among key receptors and signaling pathways involved in cancer progression is needed to improve current therapies.
Marolda, Viviana +3 more
core +1 more source
Peptide‐Incorporated Biomaterials Promote Regeneration of Peripheral Nerve Injuries
Advanced Science, Volume 13, Issue 23, 23 April 2026.Peptide‐incorporated biomaterials provide precise, tunable biological cues that mimic functional protein domains to regulate behaviors of neurons, Schwann cells, immune cells, and endothelial cells, thereby enhancing axon elongation, Schwann cell support, inflammatory microenvironment modulation, and vascularization, offering a promising alternative to
Zhiwei Zhao +5 more
wiley +1 more source
PLoS ONE, 2018 We observed in PRESTO-Tango β-arrestin recruitment assays that the α1-adrenergic receptor (AR) antagonist prazosin activates chemokine (C-X-C motif) receptor (CXCR)4. This prompted us to further examine this unexpected pharmacological behavior.
Xianlong Gao +5 more
doaj +1 more source
Frontiers in Immunology, 2023 Atypical chemokine receptors (ACKRs) form a small subfamily of receptors (ACKR1–4) unable to trigger G protein-dependent signaling in response to their ligands.
Martyna Szpakowska +10 more
doaj +1 more source
From Heterogeneity to Plasticity: Endothelial Dynamics in Lung Disease
Pulmonary Circulation, Volume 16, Issue 2, June 2026.ABSTRACT Endothelial heterogeneity and plasticity play an important role in lung development, homeostasis, and pathology. In recent years, increasing evidence has demonstrated that endothelial dysfunction contributes to the progression of various lung diseases, such as ADRS, PF, PH, and lung developmental disorders.
Van Dung Nguyen, Bisheng Zhou
wiley +1 more source
Atypical Chemokine Receptor 3 Generates Guidance Cues for CXCL12-Mediated Endothelial Cell Migration
Frontiers in Immunology, 2019 Chemokine receptor CXCR4, its ligand stromal cell-derived factor-1 (CXCL12) and the decoy receptor atypical chemokine receptor 3 (ACKR3, also named CXCR7), are involved in the guidance of migrating cells in different anatomical districts.
Chiara Tobia +8 more
doaj +1 more source
Medicine Bulletin, Volume 2, Issue 2, Page 184-204, March 2026.ABSTRACT Traditional Chinese medicine (TCM), including herbal analgesic adjuvants and acupuncture‐based interventions, has gained increasing attention as an integrative strategy for perioperative pain management in oncology. Bioactive phytochemicals—such as terpenoids, flavonoids, alkaloids, and polyphenols—exert multimodal pharmacological effects ...
Yuqin Tang +5 more
wiley +1 more source